Novocure (NVCR) Reports Phase 3 METIS Trial Met Primary Endpoint

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. META
10. TLT

Go back to Novocure (NVCR) Reports Phase 3 METIS Trial Met Primary Endpoint

Novocure (NVCR) shares jump after trial meets primary endpoint

March 27, 2024 9:58 AM EDT

Shares of Novocure (NASDAQ: NVCR) jumped Wednesday after the company reported before the open that its phase 3 METIS clinical trial met its primary endpoint.

The company's lung cancer demonstrated the slowing in the progression of cancer to the brain in... More